MannKind (NASDAQ:MNKD) Upgraded at Zacks Research

Posted by George Bondi on Oct 8th, 2026

Zacks Research upgraded shares of MannKind (NASDAQ:MNKD – Free Report) from a strong sell rating to a hold rating in a research report released on Monday,Zacks reports.

A number of other equities research analysts also recently commented on the company. Wall Street Zen downgraded MannKind from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright restated a “buy” rating on shares of MannKind in a report on Thursday, July 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of MannKind in a research report on Friday, September 11th. Wells Fargo & Company lowered their price target on MannKind from $14.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of MannKind in a research report on Friday, October 2nd. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $7.84.

Read Our Latest Stock Analysis on MannKind

MannKind Stock Performance

Shares of MNKD stock opened at $3.45 on Monday. The firm’s 50 day moving average price is $3.84 and its two-hundred day moving average price is $3.54. MannKind has a 52-week low of $2.23 and a 52-week high of $6.51. The stock has a market cap of $1.11 billion, a PE ratio of -26.54 and a beta of 1.09.

MannKind (NASDAQ:MNKD – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $109.37 million for the quarter, compared to the consensus estimate of $108.08 million. The business’s revenue was up 43.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.05 EPS. As a group, sell-side analysts predict that MannKind will post -0.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other MannKind news, Director Steven Binder sold 39,051 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $4.06, for a total value of $158,547.06. Following the completion of the transaction, the director directly owned 785,867 shares of the company’s stock, valued at approximately $3,190,620.02. The trade was a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 111,660 shares of company stock worth $414,881 in the last 90 days. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On MannKind

Hedge funds have recently modified their holdings of the business. Sequoia Financial Advisors LLC grew its position in shares of MannKind by 41.6% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 69,703 shares of the biopharmaceutical company’s stock valued at $297,000 after purchasing an additional 20,480 shares during the period. WINTON GROUP Ltd acquired a new stake in MannKind during the 2nd quarter worth approximately $197,000. Integrated Wealth Concepts LLC bought a new position in MannKind in the second quarter valued at approximately $78,000. Squarepoint Ops LLC bought a new position in MannKind in the second quarter valued at approximately $1,760,000. Finally, Allworth Financial LP boosted its holdings in shares of MannKind by 2,013.4% in the second quarter. Allworth Financial LP now owns 11,074 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 10,550 shares during the period. Institutional investors and hedge funds own 49.55% of the company’s stock.

MannKind Company Profile

(Get Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).